- AU$1.85bn
- AU$1.40bn
- AU$39.68m
Brief: Pyc Therapeutics FY Revenues From Ordinary Activities Up 22%
Australia Stock Exchange release from PYC THERAP : PRE_NR Ends: 17:40:56
Australia Stock Exchange release from PYC THERAP : Preliminary Final Report
Brief: PYC Therapeutics Forms Ophthalmology-Focused Clinical Advisory Board
Australia Stock Exchange release from PYC THERAP : August Investor Update
Australia Stock Exchange release from PYC THERAP : PYC Quarterly Investor Call - August 17
Brief: PYC Therapeutics Says Co On-Track For Investigational New Drug Application In Mid-2022
Australia Stock Exchange release from PYC THERAP : Commencement of Larger Animal Studies for Lead Program
Australia Stock Exchange release from PYC THERAP : Change of Auditor
Brief: Pyc Therapeutics Announces Comprehensive Preclinical Results Demonstrating VP-002 Program's Potential As First Disease Modifying Therapy For Autosomal Dominant Optic Atrophy
Australia Stock Exchange release from PYC THERAP : VP-002 Program - Technical Presentation
Brief: PYC Therapeutics Announces Residency At Johnson & Johnson Innovation, JLabs
Australia Stock Exchange release from PYC THERAP : Exercise of Options
Australia Stock Exchange release from PYC THERAP : Application for quotation of securities - PYC
Australia Stock Exchange release from PYC THERAP : Second Drug Program Progressing Towards Human Trials
Australia Stock Exchange release from PYC THERAP : PRE_NR Ends: 10:12:35
Brief: PYC Therapeutics Ltd Seeks Trading Halt
Australia Stock Exchange release from PYC THERAP : Trading Halt
Australia Stock Exchange release from PYC THERAP : Evercore ISI GenomeRx Emerging Therapeutic Company Day